Home LiteratureArticle Details
PMID: 54578 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial

Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.

Lancet (London, England) ·Vol. 1 ·No. 7950 ·1976-01-10 ·Pages 51-4

Jennings G, Jones MS, Besterman EM, Model DG, Turner PP, Kidner PH

Abstract

Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram. It caused a significant reduction in the incidence of ventricular arrhythmias and of the various degrees of heart-block. There was a significant reduction of reinfarction during hospital stay in patients who had received disopyramide. Disopyramide appears to be a safe and effective oral therapy in the prevention of potentially serious arrhythmias following myocardial infarction.

MeSH Terms
Administration, Oral Arrhythmias, Cardiac/etiology,prevention & control Atrial Fibrillation/epidemiology,prevention & control Clinical Trials as Topic Disopyramide/administration & dosage,adverse effects,therapeutic use Drug Evaluation Heart Block/epidemiology,prevention & control Humans Myocardial Infarction/complications Placebos Pyridines/administration & dosage Ventricular Fibrillation/epidemiology,prevention & control
Chemicals
Placebos Pyridines Disopyramide
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Jennings G
Jones M S
Besterman E M
Model D G
Turner P P
Kidner P H
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1976-01-10
Pages
51-4
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com